Pay in 4 interest-free payments of $25.00 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
The drug treatment led to tumor growth inhibition (TGI) of an EZH2 mutant KARPAS-422 DLBCL xenograft
elevated global levels of H3K4 trimethylation (H3K4me3) and decreased the number of DTPs in multiple cancer cell line models treated with standard chemotherapy or targeted agents
N-[4-[(2-Methoxyethyl)methylamino]phenyl]-2-phenyl-5-(trifluoromethyl)-4-oxazolecarboxamide
even at a concentration of 0
Ziegenfuss TN
PI-103 butyric acid (4-PBA) The drug treatment led toPI 103 is a potent, cell permeable, ATP competitive inhibitor of phosphatidylinositol 3 kinase (PI3K) family members with selectivity toward DNA PK, PI3K (p110), and mTOR. Product information CAS Number: 371935 74 9 Molecular Weight: 348. 36 Formula: C19H16N4O3 Synonym: PI103 PI 103 Chemical Name: 3 (4 morpholinopyrido[3',2': 4,5]furo[3,2 d]pyrimidin 2 yl)phenol Smiles: OC1C=C(C=CC=1)C1=NC2=C(OC3=NC=CC=C23)C(=N1)N1CCOCC1 InChiKey: TUVCWJQQGGETHL
US$ 10.00
US$ 132.95
US$ 10.00
US$ 16.99
US$ 35.95